{"text": "Novel therapies for inflammatory bowel disease .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Looking back at successes and failures in newer approaches to treating IBD , it is tempting -- although still difficult -- to draw conclusions about pathogenesis .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "When a therapy proves effective , do clinicians truly know how it works ?", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Even with a therapy as specific as anti-TNF antibody , it is not clear if the benefit is attributable to simple binding and clearance of <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> or to binding on the cell surface and subsequent deletion of the activated macrophage .", "event": "<extra_id_0> <extra_id_0> Binding binding <extra_id_0> Theme TNF-alpha <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "When a drug appears to be less effective than preclinical models suggest , can failures in effectiveness from delivery or dosing be differentiated ?", "event": "<extra_id_0> <extra_id_1>"}
{"text": "The disappointing results of clinical trials with <extra_id_0> IL-10 <extra_id_2> Protein <extra_id_1> -- so at odds with the prediction of benefit from animal models -- bring into question the validity of those models as well as the soundness of design of the clinical trials on which efficacy of <extra_id_0> IL-10 <extra_id_2> Protein <extra_id_1> is judged .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "The variability of response even to the most narrowly targeted agents suggests that these diseases are far more heterogeneous in humans than in their murine counterparts .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Clinicians are only just beginning to recognize subclinical markers of response , and it may soon be possible to predict response on the basis of genetic composition .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "For the moment , however , the field of pharmacogenetics is embryonic .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Challenges in developing new therapeutic strategies include not only identifying novel agents , but also improving the definitions of clinical endpoints and defining efficacy at the biologic level .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Only through considered evaluation of clinical evidence may clinicians determine which therapies should remain novelties and which should become an accepted part of the armamentarium .", "event": "<extra_id_0> <extra_id_1>"}
